CKD-704 (risankizumab biosimilar)
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 29, 2025
Chong Kun Dang said on the 29th it received approval from the European Medicines Agency (EMA) for a phase 1 clinical trial of CKD-704, a biosimilar psoriasis treatment.
(Chosun Biz)
- "Chong Kun Dang plans to conduct the trial in Europe with more than 200 healthy adults."
New P1 trial • Psoriasis
1 to 1
Of
1
Go to page
1